Search

ProQR Announces an Investor and Analyst Event and Pre-Clinical Data Presentations for QR-110 for LCA10 at the 2016 ARVO Annual Meeting

Press release

LEIDEN, Netherlands, April 25, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 25, 2016
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

Press release

Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th Investor conference call to be held at 8:15 am ET on Sept. 5th

August 15, 2018
ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

Press release

QR-110 demonstrated rapid and sustained improvement in vision in the majority of subjects, as measured by visual acuity and mobility course QR-110 was well-tolerated with no serious adverse events

September 05, 2018
ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases

Press release

My Retina Tracker Program is the highest volume IRD genetic testing program in the U.S.

February 06, 2020
ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

Press release

… ProQR Receives up to $5 Million in Partnership with EB … LEIDEN, the Netherlands, June 12, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, Chief Executive Officer of ProQR. “With the funding from these partners, we plan to …

June 12, 2018
ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3

Press release

… ProQR annonce des résultats intermédiaires positifs pour un … Massachusetts, 05 sept. 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), une entreprise qui … vice-président exécutif recherche et développement de ProQR. « Nous avons observé une amélioration cliniquement …

September 05, 2018